CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
paclitaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001499
NCT00001499Phase 2Completed
CompareCT.gov

Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 2 clinical trial evaluating paclitaxel, cisplatin, and 1 other intervention for Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. Completed, across 1 site.

Detailed Summary

2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung, Lung Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2002
Enrollment StartMar 1, 1996
Study CompletionJun 1, 2000
TodayJul 2, 2026
Posted 23.6 years ago

Interventions

paclitaxeldrug

cisplatindrug

chest radiotherapyprocedure